Events & Resources
Events
Register for an upcoming webinar and track which industry events our analysts attend.
Learn More →Topics
See All Topics →Latest Articles
Explore our Research →The big answers: EMARKETER Daily quiz
Article |
Aug 20, 2025
Marketers use genAI to customize video ads
Article |
Aug 20, 2025
EHR giant Epic introduces new AI scribe capabilities for doctors
Article |
Aug 20, 2025
Usage-based deals could reshape AI content monetization models
Article |
Aug 20, 2025
Google bets Pixel’s future on AI with Gemini and Magic Cue
Article |
Aug 20, 2025
Estée Lauder slumps in latest quarter, warns of $100 million tariff hit
Article |
Aug 20, 2025
OOH spurs hike in awareness
Article |
Aug 19, 2025
From hidden costs to full control: Georgia-Pacific’s programmatic pivot
Article |
Aug 19, 2025
Google’s language targeting changes could reshape bilingual strategies, reduce advertiser control
Article |
Aug 19, 2025
Prominent pediatrician association provides COVID-19 vaccine recommendations that contradict HHS
Article |
Aug 19, 2025
About
Our Methodology
Rigorous proprietary data vetting strips biases and produces superior insights.
Learn More →Already have a subscription?Sign In
Access All Charts and Data
Transparently sourced data in visual form, perfect for legitimizing your strategic ideas and thought leadership via internal and external presentations.
Access All Charts and Data
Transparently sourced data in visual form, perfect for legitimizing your strategic ideas and thought leadership via internal and external presentations.
June 11, 2024
US Employers’ and Health Plans’ Coverage of GLP-1 Drugs for Type 2 Diabetes and Obesity, June 2024 (% of respondents)
Methodology
Data is from the June 2024 Pharmaceutical Strategies Group (PSG) "Trends in Drug Benefit Design Report." 223 benefits leaders representing US employers, health plans, and unions/Taft-Hartley plans were surveyed during February 15, 2024-March 15, 2024. Employers made up the largest portion of the sample (66%), followed by health plans (29%). The survey's primary source of respondents was PSG's proprietary database of drug benefit decision-makers.Featured In
New GLP-1 users are more likely to have obesity than diabetes Eli Lilly reports $11.3B in global Q2 revenue, raises guidance by $3BRo launches GLP-1 insurance coverage checkerEli Lilly’s tirzepatide reduces diabetes risk by 94% for some patients Elevance requests repayment from doctors for overprescribing Ozempic 9amHealth taps Instacart to integrate food prescriptions into its weight loss programs Consumers overspent by $200M on weight loss medications in the past yearNovo Nordisk moves into the D2C market with steep price reduction of WegovyChart Title
US Employers’ and Health Plans’ Coverage of GLP-1 Drugs for Type 2 Diabetes and Obesity, June 2024 (% of respondents)Publication Date
June 11, 2024
